Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aevitas Therapeutics is a biopharmaceutical company focused on advancing gene therapies of short-form human factor H (sFH) to restore complement regulation in dry age-related macular degeneration (Dry AMD), atypical hemolytic uremic syndrome (aHUS), and other disorders characterized by complement dysregulation. Our sFH platform is based on an engineered, functional short-form factor H whose transgene can be cloned into adeno-a...
Aevitas Therapeutics is a biopharmaceutical company focused on advancing gene therapies of short-form human factor H (sFH) to restore complement regulation in dry age-related macular degeneration (Dry AMD), atypical hemolytic uremic syndrome (aHUS), and other disorders characterized by complement dysregulation. Our sFH platform is based on an engineered, functional short-form factor H whose transgene can be cloned into adeno-associated viruses (AAV) for delivery by gene therapy.

List your booth number for exhibitions, ask us